Divine E Ediebah1,2, Chantal Quinten3, Corneel Coens1, Jolie Ringash4,5, Janet Dancey5,6, Efstathios Zikos1, Carolyn Gotay5,7, Michael Brundage5,6,8, Dongsheng Tu5, Hans-Henning Flechtner9, Eva Greimel10, Bryce B Reeve11,12,13, Martin Taphoorn14,15, Jaap Reijneveld14,16, Linda Dirven14,15, Andrew Bottomley1. 1. Quality of Life Department, European Organization for Research and Treatment of Cancer, Brussels, Belgium. 2. Department of Neurology and Brain Tumor Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands. 3. Epidemiological Methods Section, Surveillance and Response Support Unit, European Center for Disease Prevention and Control, Stockholm, Sweden. 4. Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. 5. Canadian Cancer Trials Group, Kingston, Ontario, Canada. 6. Queen's University, Kingston, Ontario, Canada. 7. School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. 8. Cancer Centre of Southeastern Ontario, Kingston General Hospital, Kingston, Ontario, Canada. 9. Child and Adolescent Psychiatry, University Magdeburg, Magdeburg, Germany. 10. Obstetrics and Gynecology, Medical University Graz, Graz, Austria. 11. Center for Health Management, Duke University School of Medicine, Durham, North Carolina. 12. Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina. 13. Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina. 14. Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands. 15. Neurology, Haaglanden Medical Center, the Hague, the Netherlands. 16. Department of Neurology, Academic Medical Center, Amsterdam, the Netherlands.
Abstract
BACKGROUND: The aims of this study were to externally validate an established association between baseline health-related quality of life (HRQOL) scores and survival and to assess the added prognostic value of HRQOL with respect to demographic and clinical indicators. METHODS: Pooled data were analyzed from 17 randomized controlled trials opened by the Canadian Cancer Trials Group between 1991 and 2004; they included survival and baseline HRQOL data from 3606 patients with 8 different cancer sites. The models included sex, age (≤60 vs >60 years), World Health Organization performance status (0 or 1 vs 2-4), distant metastases (no vs yes), and 15 European Organization for Research and Treatment of Cancer (EORTC) Core Quality-of-Life Questionnaire (QLQ-C30) scales. Analyses were conducted with multivariate Cox proportional hazards models and were stratified by cancer site. Harrell's discrimination C-index was used to calculate the predictive accuracy of the model when HRQOL parameters were added to clinical and demographic variables. The added value of adding HRQOL scales to clinical and demographic variables was illustrated with Kaplan-Meier curves. RESULTS: In the stratified, multivariate model, HRQOL parameters-global health status (hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.95-1.00; P < . 0001), dyspnea (HR, 1.04; 95% CI, 1.02-1.06; P < . 0002), and appetite loss (HR, 1.06; 95% CI, 1.04-1.08; P < . 0001)-were independent prognostic factors in addition to the demographic and clinical variables (all P values < .05). Adding these HRQOL variables to the clinical variables resulted in an added relative prognostic value for survival of 5%. CONCLUSIONS: These results confirm previous findings showing that baseline HRQOL scores on the EORTC QLQ-C30 provide prognostic information in addition to information from clinical measures. However, the impact of specific domains may differ across studies. Cancer 2018.
BACKGROUND: The aims of this study were to externally validate an established association between baseline health-related quality of life (HRQOL) scores and survival and to assess the added prognostic value of HRQOL with respect to demographic and clinical indicators. METHODS: Pooled data were analyzed from 17 randomized controlled trials opened by the Canadian Cancer Trials Group between 1991 and 2004; they included survival and baseline HRQOL data from 3606 patients with 8 different cancer sites. The models included sex, age (≤60 vs >60 years), World Health Organization performance status (0 or 1 vs 2-4), distant metastases (no vs yes), and 15 European Organization for Research and Treatment of Cancer (EORTC) Core Quality-of-Life Questionnaire (QLQ-C30) scales. Analyses were conducted with multivariate Cox proportional hazards models and were stratified by cancer site. Harrell's discrimination C-index was used to calculate the predictive accuracy of the model when HRQOL parameters were added to clinical and demographic variables. The added value of adding HRQOL scales to clinical and demographic variables was illustrated with Kaplan-Meier curves. RESULTS: In the stratified, multivariate model, HRQOL parameters-global health status (hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.95-1.00; P < . 0001), dyspnea (HR, 1.04; 95% CI, 1.02-1.06; P < . 0002), and appetite loss (HR, 1.06; 95% CI, 1.04-1.08; P < . 0001)-were independent prognostic factors in addition to the demographic and clinical variables (all P values < .05). Adding these HRQOL variables to the clinical variables resulted in an added relative prognostic value for survival of 5%. CONCLUSIONS: These results confirm previous findings showing that baseline HRQOL scores on the EORTC QLQ-C30 provide prognostic information in addition to information from clinical measures. However, the impact of specific domains may differ across studies. Cancer 2018.
Authors: C Quinten; C Kenis; L Decoster; P R Debruyne; I De Groof; C Focan; F Cornelis; V Verschaeve; C Bachmann; D Bron; S Luce; G Debugne; H Van den Bulck; J C Goeminne; A Baitar; K Geboers; B Petit; C Langenaeken; R Van Rijswijk; P Specenier; G Jerusalem; J P Praet; K Vandenborre; M Lycke; J Flamaing; K Milisen; J P Lobelle; H Wildiers Journal: Qual Life Res Date: 2018-12-03 Impact factor: 4.147
Authors: Olga Husson; Belle H de Rooij; Jacobien Kieffer; Simone Oerlemans; Floortje Mols; Neil K Aaronson; Winette T A van der Graaf; Lonneke V van de Poll-Franse Journal: Oncologist Date: 2019-10-31
Authors: David Hui; Carlos Eduardo Paiva; Egidio G Del Fabbro; Christopher Steer; Jane Naberhuis; Marianne van de Wetering; Paz Fernández-Ortega; Tatsuya Morita; Sang-Yeon Suh; Eduardo Bruera; Masanori Mori Journal: Support Care Cancer Date: 2019-03-13 Impact factor: 3.603
Authors: Nadja Klafke; Cornelia Mahler; Cornelia von Hagens; Lorenz Uhlmann; Martina Bentner; Andreas Schneeweiss; Andreas Mueller; Joachim Szecsenyi; Stefanie Joos Journal: Cancer Med Date: 2019-05-21 Impact factor: 4.452
Authors: Lari Wenzel; Kathryn Osann; Chelsea McKinney; David Cella; Giulia Fulci; Mary J Scroggins; Heather A Lankes; Victoria Wang; Kenneth P Nephew; George L Maxwell; Samuel C Mok; Thomas P Conrads; Austin Miller; Robert S Mannel; Heidi J Gray; Parviz Hanjani; Warner K Huh; Nick Spirtos; Mario M Leitao; Gretchen Glaser; Sudarshan K Sharma; Alessandro D Santin; Paul Sperduto; Shashikant B Lele; Robert A Burger; Bradley J Monk; Michael Birrer Journal: J Natl Cancer Inst Date: 2021-10-01 Impact factor: 13.506
Authors: Olga Husson; Belle H de Rooij; Jacobien Kieffer; Simone Oerlemans; Floortje Mols; Neil K Aaronson; Winette T A van der Graaf; Lonneke V van de Poll-Franse Journal: Oncologist Date: 2019-10-31